Utilization of neoadjuvant chemotherapy in high‐risk, node‐negative early breast cancer

BACKGROUND: Controversy exists regarding the optimal sequence of chemotherapy among women with operable node‐negative breast cancers with high‐risk tumor biology. We evaluated national patterns of neoadjuvant chemotherapy (NACT) use among women with early‐stage HER2+, triple‐negative (TNBC), and hig...

Descripción completa

Detalles Bibliográficos
Autores principales: Prakash, Ipshita, Neely, N. Ben, Thomas, Samantha M., Sammons, Sarah, Blitzblau, Rachel C., DiLalla, Gayle A., Hyslop, Terry, Menendez, Carolyn S., Plichta, Jennifer K., Rosenberger, Laura H., Fayanju, Oluwadamilola M., Hwang, E. Shelley, Greenup, Rachel A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8855910/
https://www.ncbi.nlm.nih.gov/pubmed/34989142
http://dx.doi.org/10.1002/cam4.4517

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8855910/
https://www.ncbi.nlm.nih.gov/pubmed/34989142
http://dx.doi.org/10.1002/cam4.4517

Ejemplares similares